Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
B: Arm Label: Anti-TNFa regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: Anti IL12/23 regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Cyclosporine regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclosporine | Arm Label: anti-interleukin 17 A regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Arm Label: inhibitor of phosphodiesterase-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Anti-TNFa regimen | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Anti IL12/23 regimen | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): Cyclosporine regimen | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): anti-interleukin 17 A regimen | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): inhibitor of phosphodiesterase-4
C: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab
D: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment

Answer: C